Alpha DNA Investment Management’s Colgate-Palmolive CL Stock Holding History

Alpha DNA Investment Management’s Portfolio CL Stock Details CL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-21,058	Closed	-$1.91M	–	43
2024 Q4	$1.91M	Buy	21,058 +274	+1%	+$26.1K	0.73%	26
2024 Q3	$2.16M	Sell	20,784 -3,155	-13%	-$322K	0.81%	20
2024 Q2	$2.32M	Buy	+23,939	New	+$2.21M	0.9%	13
2023 Q4	–	Sell	-24,532	Closed	-$1.74M	–	196
2023 Q3	$1.74M	Buy	+24,532	New	+$1.83M	0.71%	27
2021 Q2	–	Sell	-801	Closed	-$62K	–	198
2021 Q1	$62K	Buy	801 +120	+18%	+$9.41K	0.07%	145
2020 Q4	$58K	Buy	+681	New	+$56.3K	0.06%	162

Other funds holding CL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Alpha DNA Investment Management's CL Position: Q1 2025 in Review

Alpha DNA Investment Management sold out of Colgate-Palmolive (CL) in Q1 2025, closing a stake of 21,058 shares — an estimated $1.91M sold.

Alpha DNA Investment Management first reported a position in CL in Q4 2020 and held it in 6 quarters. The position peaked at $2.32M in Q2 2024. 1,942 funds tracked by Wall St. Rank hold CL as of Q1 2025.

Alpha DNA Investment Management reported no remaining Colgate-Palmolive position as of Q1 2025 after selling out during the quarter.
Alpha DNA Investment Management sold 21,058 Colgate-Palmolive shares in Q1 2025, an estimated $1.91M.
Alpha DNA Investment Management first reported a position in Colgate-Palmolive in Q4 2020 and held it in 6 quarters.
Alpha DNA Investment Management's Colgate-Palmolive position peaked at $2.32M in Q2 2024.
1,942 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q1 2025.

Based on Alpha DNA Investment Management's 13F filing for Q1 2025, filed 19 May 2025.